The tyrosine kinase inhibitors targeting the BCR-ABL oncogene have profoundly changed the treatment regimen for CML by reaching sustained remission and prolonged survival. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.